VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that its lateral flow finger-prick prototype for the Nu.Q NETs test demonstrated strong correlation with its established automated assay in critically ill sepsis patients. The findings, presented as part of the SUMMIT program, suggest that nucleosome testing could move beyond centralized laboratories and be performed at the point of care, enabling faster clinical decisions in emergency rooms, intensive care units, and potentially even in patients' homes.
The study evaluated capillary blood and plasma samples from intensive care patients, comparing results from the prototype with the company's CE-marked laboratory assay. The lateral flow test showed a Spearman correlation of 0.85 and a Pearson correlation of 0.881, indicating a significant agreement between the two methods. VolitionRx highlighted that this decentralized format could facilitate rapid identification of high-risk patients, allowing for earlier intervention and potentially improving outcomes in sepsis, a condition where timely treatment is critical.
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and it remains a major global health challenge, especially in low- and middle-income countries where access to centralized laboratory infrastructure is limited. The ability to perform nucleosome testing at the bedside or in community settings could expand access to this biomarker, which is associated with NETosis, a process implicated in sepsis pathology. By bringing testing closer to the patient, clinicians could make quicker triage and treatment decisions, potentially reducing mortality and healthcare costs.
The implications of this development are substantial. If the lateral flow prototype is successfully commercialized, it could transform how sepsis is managed, particularly in resource-limited settings. It could also broaden the application of nucleosome testing to other diseases associated with NETosis, such as certain cancers and autoimmune conditions. Moreover, the convenience of a finger-prick test could facilitate more frequent monitoring of chronic conditions, enabling proactive management and earlier detection of disease progression.
VolitionRx's research and development activities are centered in Belgium, with additional facilities in the U.S. and the U.K. The company is dedicated to advancing epigenetics and developing simple, cost-effective blood tests for early detection and monitoring of life-altering diseases. This latest announcement underscores its commitment to innovation and its potential to make a significant impact on global health.
For more information about VolitionRx and its pipeline, visit the company's website at https://volition.com/. The full press release is available at https://ibn.fm/81Vlm.
